Affinity Biopharma, a clinical-stage, oncology-focused biopharma and platform company focused on Tumor MicroEnvironment Activated (TMEA) therapeutics and local drug activation, announced the abstracts publication and presentation in the Poster Session at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting during April 25-30 in Chicago, Illinois. These abstracts cover the preclinical data of our novel tumor microenvironment-activated (TMEA) anti-CTLA-4 antibody and our dual-payload TMEA-ADC platform.

The following are the details for the abstracts and poster presentations:

Presentation Title: Dual-payload TME-activated ADC platform

Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Drug Delivery Technologies
Session Start: 4/28/2025 9:00:00 AM
Session End: 4/28/2025 12:00:00 PM
Location: Poster Section 23
Poster Board Number: 24

Presentation Title: A novel chemical conjugated anti-CTLA-4 antibody with tumor microenvironment activation

Session Category: Clinical Research
Session Title: Therapeutic Antibodies, Including Engineered Antibodies 2
Session Start: 4/29/2025 2:00:00 PM
Session End: 4/29/2025 5:00:00 PM
Location: Poster Section 35
Poster Board Number: 19